Literature DB >> 7697134

Provocative chelation with DMSA and EDTA: evidence for differential access to lead storage sites.

B K Lee1, B S Schwartz, W Stewart, K D Ahn.   

Abstract

OBJECTIVES--To validate a provocative chelation test with 2,3-dimercaptosuccinic acid (DMSA) by direct comparison with the standard ethylene diamine tetraacetic acid (EDTA) test in the same subjects; and to compare and contrast the predictors of lead excretion after DMSA with those after EDTA. A metal chelating agent given orally, DMSA may mobilise and enhance the excretion of lead from the storage sites in the body that are most directly relevant to the health effects of lead. A provocative chelation test with DMSA could thus have wide potential application in clinical care and epidemiological studies. METHODS--34 male lead workers in the Republic of Korea were given a single oral dose of 10 mg/kg DMSA, urine was collected over the next eight to 24 hours, and urine volume and urinary lead concentration determined at 0, 2, 4, 6, 8, and 24 hours. Either two weeks before or two weeks after the dose of DMSA 17 of these workers also received 1 g intravenous EDTA followed by an eight hour urine collection with fractionation at 0, 2, 4, 6, and 8 hours. RESULTS--Urinary lead concentration peaked at two hours after DMSA and four hours after EDTA. Lead excretion after DMSA was less than after EDTA, and cumulative excretion after DMSA plateaued at six to eight hours. The two hour and four hour cumulative lead excretions after DMSA were highly correlated with the eight hour total (r = 0.76 and 0.95). In multiple linear regression analyses, blood lead was found to be an important predictor of EDTA-chelatable lead, whereas urinary aminolevulinic acid (ALAU) was associated with DMSA-chelatable lead. Notably, lead excretion after DMSA was greatly increased if EDTA was given first. An earlier dose of EDTA also modified the relation between ALAU and DMSA-chelatable lead in that workers who received EDTA before DMSA showed a much steeper dose-response relation between these two measures. CONCLUSIONS--The predictors of lead excretion after DMSA and EDTA are different and an earlier dose of EDTA may increase lead excretion after a subsequent dose of DMSA. The results suggest that two hour or four hour cumulative lead excretion after DMSA may provide an estimate of lead in storage sites that are most directly relevant to the health effects of lead.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697134      PMCID: PMC1128144          DOI: 10.1136/oem.52.1.13

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  31 in total

1.  Mobilisation of heavy metals into the urine by CaEDTA: relation to erythrocyte and plasma concentrations and exposure indicators.

Authors:  S Araki; H Aono; K Murata
Journal:  Br J Ind Med       Date:  1986-09

2.  Comparison of two in vitro methods of bone lead analysis and the implications for in vivo measurements.

Authors:  L J Somervaille; D R Chettle; M C Scott; A C Aufderheide; J E Wallgren; L E Wittmers; G R Rapp
Journal:  Phys Med Biol       Date:  1986-11       Impact factor: 3.609

3.  Meso-2,3-dimercaptosuccinic acid in the diagnosis and treatment of lead poisoning.

Authors:  Y Bentur; J G Brook; R Behar; U Taitelman
Journal:  J Toxicol Clin Toxicol       Date:  1987

4.  2,3-Dimercaptosuccinic acid as an antidote for lead intoxication.

Authors:  J H Graziano; E S Siris; N LoIacono; S J Silverberg; L Turgeon
Journal:  Clin Pharmacol Ther       Date:  1985-04       Impact factor: 6.875

5.  Disposition of [14C]dimercaptosuccinic acid in mice.

Authors:  Y Y Liang; C Marlowe; W J Waddell
Journal:  Fundam Appl Toxicol       Date:  1986-04

6.  Subclinical cervico-spino-bulbar effects of lead: a study of short-latency somatosensory evoked potentials in workers exposed to lead, zinc, and copper.

Authors:  S Araki; K Murata; H Aono
Journal:  Am J Ind Med       Date:  1986       Impact factor: 2.214

7.  2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans.

Authors:  L Fournier; G Thomas; R Garnier; A Buisine; P Houze; F Pradier; S Dally
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

8.  Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy.

Authors:  D A Cory-Slechta
Journal:  J Pharmacol Exp Ther       Date:  1988-07       Impact factor: 4.030

9.  Reversibility of psychological performance in subclinical lead absorption.

Authors:  K Yokoyama; S Araki; H Aono
Journal:  Neurotoxicology       Date:  1988       Impact factor: 4.294

10.  Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy.

Authors:  D A Cory-Slechta; B Weiss; C Cox
Journal:  J Pharmacol Exp Ther       Date:  1987-12       Impact factor: 4.030

View more
  10 in total

1.  Predictors of DMSA chelatable lead, tibial lead, and blood lead in 802 Korean lead workers.

Authors:  A C Todd; B K Lee; G S Lee; K D Ahn; E L Moshier; B S Schwartz
Journal:  Occup Environ Med       Date:  2001-02       Impact factor: 4.402

2.  delta-Aminolevulinic acid dehydratase genotype modifies four hour urinary lead excretion after oral administration of dimercaptosuccinic acid.

Authors:  B S Schwartz; B K Lee; W Stewart; P Sithisarankul; P T Strickland; K D Ahn; K Kelsey
Journal:  Occup Environ Med       Date:  1997-04       Impact factor: 4.402

3.  Predictors of dimercaptosuccinic acid chelatable lead and tibial lead in former organolead manufacturing workers.

Authors:  B S Schwartz; W F Stewart; A C Todd; J M Links
Journal:  Occup Environ Med       Date:  1999-01       Impact factor: 4.402

Review 4.  Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy.

Authors:  Gervasio A Lamas; Ana Navas-Acien; Daniel B Mark; Kerry L Lee
Journal:  J Am Coll Cardiol       Date:  2016-05-24       Impact factor: 24.094

5.  Associations of blood pressure and hypertension with lead dose measures and polymorphisms in the vitamin D receptor and delta-aminolevulinic acid dehydratase genes.

Authors:  B K Lee; G S Lee; W F Stewart; K D Ahn; D Simon; K T Kelsey; A C Todd; B S Schwartz
Journal:  Environ Health Perspect       Date:  2001-04       Impact factor: 9.031

Review 6.  The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues.

Authors:  Howard Hu; Regina Shih; Stephen Rothenberg; Brian S Schwartz
Journal:  Environ Health Perspect       Date:  2006-12-22       Impact factor: 9.031

7.  Diagnostic chelation challenge with DMSA: a biomarker of long-term mercury exposure?

Authors:  H Frumkin; C C Manning; P L Williams; A Sanders; B B Taylor; M Pierce; L Elon; V S Hertzberg
Journal:  Environ Health Perspect       Date:  2001-02       Impact factor: 9.031

8.  Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with polymorphisms in the vitamin D receptor and [delta]-aminolevulinic acid dehydratase genes.

Authors:  B S Schwartz; B K Lee; G S Lee; W F Stewart; D Simon; K Kelsey; A C Todd
Journal:  Environ Health Perspect       Date:  2000-10       Impact factor: 9.031

Review 9.  A Review on Coordination Properties of Thiol-Containing Chelating Agents Towards Mercury, Cadmium, and Lead.

Authors:  Geir Bjørklund; Guido Crisponi; Valeria Marina Nurchi; Rosita Cappai; Aleksandra Buha Djordjevic; Jan Aaseth
Journal:  Molecules       Date:  2019-09-06       Impact factor: 4.411

10.  Treatment of lead and arsenic poisoning in anuric patients - a case report and narrative review of the literature.

Authors:  Chun-Yuan Hsiao; Chip Gresham; Mark R Marshall
Journal:  BMC Nephrol       Date:  2019-10-17       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.